AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15220241 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (15 to 45 mg, titrated based on tolerability)
Number of subjects: 5238
Study 15220241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5238
Study 11176310 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-field extremity MR system (E-MRI: 0.2 T) with T2-weighted turbo SE (TSE) sequences
Number of subjects: 22
Study 11176310 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-field extremity MR system (E-MRI: 0.2 T) with MTC sequences
Number of subjects: 22
Study 11176310 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-field extremity MR system (E-MRI: 0.2 T) with T1-weighted SE sequences
Number of subjects: 22
Study 11176310 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-field extremity MR system (E-MRI: 0.2 T) with T2-weighted TSE sequences
Number of subjects: 22
Study 9702847 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release tablet of naproxen (500 mg once daily)
Number of subjects: 0
Study 9702847 — intervention group
Group type: COMPARATOR
Intervention: Conventional tablet of naproxen (250 mg twice daily)
Number of subjects: 0
Study 7971867 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-session, skills-based HIV prevention curriculum implemented by trained teachers
Number of subjects: 2844
Study 7971867 — intervention group
Group type: COMPARATOR
Intervention: Comparison condition (no intervention)
Number of subjects: 2844
Study 2478790 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg UD-CG 115 BS (pimobendan)
Number of subjects: 12
Study 2478790 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg UD-CG 115 BS (pimobendan)
Number of subjects: 12
Study 335788 — intervention group
Group type: EXPERIMENTAL
Intervention: Pizotifen (4-10 mg daily)
Number of subjects: 20
Study 335788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29118014 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (12-week supervised program)
Number of subjects: 22
Study 27137926 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel coils
Number of subjects: 484
Study 27137926 — intervention group
Group type: COMPARATOR
Intervention: Bare platinum coils
Number of subjects: 484
Study 25350037 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic and strength conditioning exercise
Number of subjects: 63
Study 25350037 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 63
Study 22153550 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartMate II continuous-flow LVAD
Number of subjects: 126
Study 22153550 — intervention group
Group type: COMPARATOR
Intervention: HeartMate XVE pulsatile-flow LVAD
Number of subjects: 126
Study 20459012 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human epidermal growth factor (rhEGF) with silver sulfadiazine (SD‐Ag)
Number of subjects: 80
Study 20459012 — intervention group
Group type: COMPARATOR
Intervention: Silver sulfadiazine (SD‐Ag)
Number of subjects: 80
Study 18624588 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT) - Individual format (CBT-I)
Number of subjects: 112
Study 18624588 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT) - Group format (CBT-G)
Number of subjects: 112
Study 18624588 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT) - Individual format (IPT-I)
Number of subjects: 112
Study 18624588 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT) - Group format (IPT-G)
Number of subjects: 112
Study 15691863 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine (ACh) in type 2 diabetic patients
Number of subjects: 103
Study 15691863 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) in type 2 diabetic patients
Number of subjects: 103
Study 15691863 — intervention group
Group type: EXPERIMENTAL
Intervention: ACh/SNP ratio in type 2 diabetic patients
Number of subjects: 103
Study 15691863 — intervention group
Group type: COMPARATOR
Intervention: ACh/SNP ratio in control subjects
Number of subjects: 103
Study 12665638 — intervention group
Group type: COMPARATOR
Intervention: Standard letter recommending central bone density screening (DXA)
Number of subjects: 197
Study 12665638 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended letter outlining treatment strategies based on subsequent central DXA scan results
Number of subjects: 197
Study 12665638 — intervention group
Group type: COMPARATOR
Intervention: Standard letter
Number of subjects: 197
Study 12665638 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended letter
Number of subjects: 197
Study 12665638 — intervention group
Group type: COMPARATOR
Intervention: Screening for T </= 1.0
Number of subjects: 197
Study 12665638 — intervention group
Group type: COMPARATOR
Intervention: Before screening
Number of subjects: 197
Study 12665638 — intervention group
Group type: EXPERIMENTAL
Intervention: After physicians received letters
Number of subjects: 197
Study 10560596 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 50 mg twice a day
Number of subjects: 1003
Study 10560596 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 100 mg twice a day
Number of subjects: 1003
Study 10560596 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg twice a day
Number of subjects: 1003
Study 10560596 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg twice a day
Number of subjects: 1003
Study 10560596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1003
Study 8735396 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% cocaine
Number of subjects: 29
Study 8735396 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% lignocaine with adrenaline (1:1000)
Number of subjects: 29
Study 8735396 — intervention group
Group type: COMPARATOR
Intervention: Both agents
Number of subjects: 29
Study 1879032 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic group (eleutherosides treatment)
Number of subjects: 57
Study 1879032 — intervention group
Group type: COMPARATOR
Intervention: Control group (insulin and potassium chloride treatment)
Number of subjects: 57
Study 6461243 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg of ferrous sulphate
Number of subjects: 135
Study 6461243 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg of ferrous sulphate
Number of subjects: 135
Study 6461243 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 mg of ferrous sulphate
Number of subjects: 135
Study 6461243 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 135
Study 30081576 — intervention group
Group type: EXPERIMENTAL
Intervention: Low FODMAP Gluten-Free Diet (LF-GFD)
Number of subjects: 50
Study 30081576 — intervention group
Group type: COMPARATOR
Intervention: Regular Gluten-Free Diet (R-GFD)
Number of subjects: 50
Study 26603110 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of remifentanil (REM) at 0.05 μg/kg/min
Number of subjects: 62
Study 26603110 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 62
Study 26603110 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of remifentanil (REM)
Number of subjects: 62
Study 24884504 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus docetaxel (GD)
Number of subjects: 337
Study 24884504 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (D)
Number of subjects: 337
Study 24884504 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMP-1 positive tumors
Number of subjects: 337
Study 24884504 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMP-1 negative tumors
Number of subjects: 337
Study 22994060 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% procaine electrophoresis
Number of subjects: 95
Study 22994060 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesotherapy with 2% procaine solution
Number of subjects: 95
Study 22994060 — intervention group
Group type: COMPARATOR
Intervention: Procaine galvanization
Number of subjects: 95
Study 22994060 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% physiological solution)
Number of subjects: 95
Study 20200964 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 IU of cholecalciferol and 1000 mg of calcium (calcium carbonate)
Number of subjects: 3195
Study 20200964 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 3195
Study 18005834 — intervention group
Group type: EXPERIMENTAL
Intervention: Midpalatal implant
Number of subjects: 51
Study 18005834 — intervention group
Group type: COMPARATOR
Intervention: Headgear
Number of subjects: 51
Study 16223887 — intervention group
Group type: EXPERIMENTAL
Intervention: Model I (using THC)
Number of subjects: 38
Study 16223887 — intervention group
Group type: EXPERIMENTAL
Intervention: Model II (using THCCOOH to THC ratio)
Number of subjects: 38
Study 16223887 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of models I and II
Number of subjects: 38
Study 12297390 — intervention group
Group type: EXPERIMENTAL
Intervention: TA-CIN vaccine (533 micro g dose)
Number of subjects: 40
Study 12297390 — intervention group
Group type: EXPERIMENTAL
Intervention: TA-CIN vaccine (26, 128, 533 micro g doses)
Number of subjects: 40
Study 12297390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 10207661 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0
Study 10207661 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 0
Study 10207661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8652235 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenograstim 0.5 micrograms/kg
Number of subjects: 66
Study 8652235 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenograstim 2 micrograms/kg
Number of subjects: 66
Study 8652235 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenograstim 5 micrograms/kg
Number of subjects: 66
Study 8652235 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenograstim 10 micrograms/kg
Number of subjects: 66
Study 8652235 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 66
Study 8652235 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenograstim (0.5 and 2 micrograms/kg)
Number of subjects: 66
Study 8652235 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenograstim (5 micrograms/kg)
Number of subjects: 66
Study 2190504 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative acute normovolemic hemodilution (PANH)
Number of subjects: 15
Study 6258838 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg)
Number of subjects: 6
Study 6258838 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg)
Number of subjects: 6
Study 6258838 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg)
Number of subjects: 6
Study 6258838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 30361270 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia initiated within 6 hours of symptom onset using surface cooling pads and cold saline, continued in the cath lab with endovascular cooling (target temperature: ≤35°C at time of reperfusion).
Number of subjects: 101
Study 30361270 — intervention group
Group type: COMPARATOR
Intervention: Not cooled (control group).
Number of subjects: 101
Study 30361270 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia group.
Number of subjects: 101
Study 30361270 — intervention group
Group type: COMPARATOR
Intervention: Control group.
Number of subjects: 101
Study 30361270 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups.
Number of subjects: 101
Study 30361270 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CMR follow-up).
Number of subjects: 101
Study 28070985 — intervention group
Group type: EXPERIMENTAL
Intervention: Causal mediation analysis with covariate adjustment
Number of subjects: 0
Study 28070985 — intervention group
Group type: COMPARATOR
Intervention: Default maximum likelihood methods
Number of subjects: 0
Study 25200570 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 2.5 mg twice daily
Number of subjects: 400
Study 25200570 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg twice daily
Number of subjects: 400
Study 25200570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 23597838 — intervention group
Group type: EXPERIMENTAL
Intervention: Anode over the left frontal cortex/cathode over the right supraorbital area
Number of subjects: 90
Study 23597838 — intervention group
Group type: EXPERIMENTAL
Intervention: Anode over the left fronto-temporal cortex/cathode over the right supraorbital area
Number of subjects: 90
Study 23597838 — intervention group
Group type: EXPERIMENTAL
Intervention: Anode over the left fronto-temporal cortex/cathode over the right fronto-temporal cortex
Number of subjects: 90
Study 23597838 — intervention group
Group type: EXPERIMENTAL
Intervention: Anode over the left fronto-temporal cortex/big-size cathode over the right supraorbital area
Number of subjects: 90
Study 23597838 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 90
Study 21244422 — intervention group
Group type: EXPERIMENTAL
Intervention: Foster care intervention
Number of subjects: 103
Study 21244422 — intervention group
Group type: COMPARATOR
Intervention: Institutional care (control)
Number of subjects: 103
Study 19307440 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous radiofrequency ablation (RFA)
Number of subjects: 0
Study 19307440 — intervention group
Group type: COMPARATOR
Intervention: Traditional and endovenous procedures
Number of subjects: 0
Study 20302683 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine hydrochloride nasal spray, 0.6% (OLO) + Fluticasone nasal spray, 50 micrograms (FNS)
Number of subjects: 0
Study 20302683 — intervention group
Group type: COMPARATOR
Intervention: Azelastine nasal spray, 0.1% (AZE) + Fluticasone nasal spray, 50 micrograms (FNS)
Number of subjects: 0
Study 15602116 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine
Number of subjects: 0
Study 15602116 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0
Study 15602116 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline alone
Number of subjects: 0
Study 15602116 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline with cognitive behavioural therapy
Number of subjects: 0
Study 12037733 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (untreated hyperthyroid GD patients)
Number of subjects: 44
Study 12037733 — intervention group
Group type: COMPARATOR
Intervention: Group II (treated euthyroid GD patients)
Number of subjects: 44
Study 12037733 — intervention group
Group type: EXPERIMENTAL
Intervention: All GD patients
Number of subjects: 44
Study 10537240 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and self-care education added to pharmaceutical treatment
Number of subjects: 105
Study 10537240 — intervention group
Group type: COMPARATOR
Intervention: Control groups (published data, age- and sex-matched group, and 211 patients with angina pectoris symptoms)
Number of subjects: 105
Study 7491852 — intervention group
Group type: EXPERIMENTAL
Intervention: U technique (no-scalpel vas deferens holding forceps)
Number of subjects: 82
Study 7491852 — intervention group
Group type: COMPARATOR
Intervention: Standard technique
Number of subjects: 82
Study 7491852 — intervention group
Group type: EXPERIMENTAL
Intervention: U technique
Number of subjects: 82
Study 2112882 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human alpha-interferon (4 million units per day, three times weekly for 16 weeks)
Number of subjects: 26
Study 369300 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium medication (24 mval/day to 36 mval/day)
Number of subjects: 24
Study 369300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 12160159 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic brimonidine
Number of subjects: 31
Study 12160159 — intervention group
Group type: COMPARATOR
Intervention: Control (no brimonidine)
Number of subjects: 31
Study 30428772 — intervention group
Group type: EXPERIMENTAL
Intervention: manualised short-term psychoanalytic child psychotherapy (mPCP)
Number of subjects: 32
Study 30428772 — intervention group
Group type: COMPARATOR
Intervention: treatment as usual (TaU)
Number of subjects: 32
Study 27267429 — intervention group
Group type: EXPERIMENTAL
Intervention: Bouillons fortified with FePP only
Number of subjects: 24
Study 27267429 — intervention group
Group type: EXPERIMENTAL
Intervention: Bouillons fortified with FeSO4 only
Number of subjects: 24
Study 27267429 — intervention group
Group type: EXPERIMENTAL
Intervention: Bouillons fortified with FeSO4+NaPP
Number of subjects: 24
Study 27267429 — intervention group
Group type: EXPERIMENTAL
Intervention: Bouillons fortified with FePP+NaPP
Number of subjects: 24
Study 24903467 — intervention group
Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl (20 mg once daily)
Number of subjects: 2185
Study 24903467 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2185
Study 22144723 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive training (5 hours of study time)
Number of subjects: 100
Study 22144723 — intervention group
Group type: COMPARATOR
Intervention: Self-study (5 hours of study time)
Number of subjects: 100
Study 20837942 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 0
Study 20837942 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 0
Study 18413111 — intervention group
Group type: EXPERIMENTAL
Intervention: SADBE sensitization doses (12.5, 25, 50, or 250 microg)
Number of subjects: 50
Study 18413111 — intervention group
Group type: COMPARATOR
Intervention: Elicitation doses (0, 0.2, 2, 20, and 200 microg)
Number of subjects: 50
Study 16103584 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine plus sulfadoxine‐pyrimethamine
Number of subjects: 3000
Study 16103584 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine plus sulfadoxine‐pyrimethamine
Number of subjects: 3000
Study 16103584 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine plus artesunate
Number of subjects: 3000
Study 11817501 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone 100 mg
Number of subjects: 11
Study 11817501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 10220927 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.5 or 0.8 g/kg)
Number of subjects: 24
Study 10220927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 7484026 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative intake of clear fluids up to 2 hours before general anaesthesia
Number of subjects: 12
Study 7484026 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 12
Study 2126219 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimozide
Number of subjects: 1
Study 2126219 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine + Pimozide
Number of subjects: 1
Study 2126219 — intervention group
Group type: COMPARATOR
Intervention: Fluvoxamine
Number of subjects: 1
Study 2126219 — intervention group
Group type: COMPARATOR
Intervention: Pimozide alone
Number of subjects: 1
Study 760861 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily chemotherapy with reinforcements every 3 months
Number of subjects: 0
Study 760861 — intervention group
Group type: COMPARATOR
Intervention: Reinforcement therapy only every 6 weeks
Number of subjects: 0
Study 760861 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytosine arabinoside and an anthracycline for remission induction
Number of subjects: 0
Study 31756300 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-fitted footwear (Clarks® footwear)
Number of subjects: 33
Study 31756300 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 33
Study 30866973 — intervention group
Group type: EXPERIMENTAL
Intervention: LOCI intervention
Number of subjects: 0
Study 29963766 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural insights (BI) reminders
Number of subjects: 8999
Study 29963766 — intervention group
Group type: COMPARATOR
Intervention: Standard reminders (control)
Number of subjects: 8999
Study 29963766 — intervention group
Group type: EXPERIMENTAL
Intervention: Primer plus BI reminders
Number of subjects: 8999
Study 29963766 — intervention group
Group type: COMPARATOR
Intervention: Primer (control)
Number of subjects: 8999
Study 27815950 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Number of subjects: 29
Study 27815950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 25077418 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 (commercial-scale lots)
Number of subjects: 160
Study 25077418 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 (pooled commercial-scale lots)
Number of subjects: 160
Study 25077418 — intervention group
Group type: COMPARATOR
Intervention: Pilot-scale lot
Number of subjects: 160
Study 22214885 — intervention group
Group type: EXPERIMENTAL
Intervention: Actions enabling benefit from misfortune (e.g., betting on stock decline)
Number of subjects: 0
Study 22214885 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptions of actor's wicked desires
Number of subjects: 0
Study 20083921 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation (PSV)
Number of subjects: 14
Study 20083921 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurally Adjusted Ventilatory Assist (NAVA)
Number of subjects: 14
Study 17284249 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (25, 50, and 100 mg)
Number of subjects: 180
Study 17284249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 16126118 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril and 120 mg diltiazem
Number of subjects: 36
Study 16126118 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 36
Study 11791949 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR
Number of subjects: 30
Study 11791949 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 30
Study 11791949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 11791949 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR and Methylphenidate
Number of subjects: 30